Literature DB >> 3708202

Interaction of amrinone with endogenous adenosine in guinea-pig atria.

P Dorigo, I Maragno.   

Abstract

In spontaneously beating atria from reserpine-treated guinea-pigs, amrinone (10 microM to 2 mM) induced a positive inotropic and chronotropic effect that was preceded by a transient reduction in contractile force and in frequency. Both the positive and negative effects were concentration-dependent. The inotropic action of amrinone was antagonized by low concentrations of 8-phenyltheophylline that compete with adenosine at R-receptors on plasma membrane without significantly influencing phosphodiesterase activity. Cumulative concentrations of amrinone (1 mM) antagonized the reduction of rate of contraction and amplitude induced by dipyridamole 1 microM in spontaneously beating atria and restored the maximum contractile effect reached in the absence of dipyridamole. In spontaneously beating preparations incubated in the presence of adenosine deaminase (1 u ml-1), amrinone lost its positive effects on the atria and only reduction of rate and contractile force was evident. Both effects were antagonized by scopolamine 1 mM thus indicating their cholinergic nature. Adenosine at 0.1 microM and 0.5 microM significantly inhibited the inotropic effect induced by amrinone (0.03 to 3 mM) and the concentration-effect curves of amrinone obtained in the absence and presence of adenosine clearly indicate a competitive antagonism between the two drugs. Thus the contractile activity of amrinone in spontaneously beating atria from reserpine-treated guinea-pigs originates from a displacement of adenosine from its R-receptor sites in the cardiac cell.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708202      PMCID: PMC1916808          DOI: 10.1111/j.1476-5381.1986.tb14578.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity.

Authors:  F W Smellie; C W Davis; J W Daly; J N Wells
Journal:  Life Sci       Date:  1979-06-25       Impact factor: 5.037

2.  Hydroxylated chlorpromazine metabolites: positive inotropic action and the release of catecholamines.

Authors:  K Temma; T Akera; T M Brody
Journal:  Mol Pharmacol       Date:  1977-11       Impact factor: 4.436

3.  Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one].

Authors:  A A Alousi; A E Farah; G Y Lesher; C J Opalka
Journal:  Circ Res       Date:  1979-11       Impact factor: 17.367

4.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

Authors:  R F Bruns
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

5.  Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy.

Authors:  W Grossman; L P McLaurin; E L Rolett
Journal:  Cardiovasc Res       Date:  1979-09       Impact factor: 10.787

6.  Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure.

Authors:  N A Klein; S J Siskind; W H Frishman; E H Sonnenblick; T H LeJemtel
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

7.  Differential effects of amrinone on contractility and taurine influx in rat and guinea pig hearts.

Authors:  J Azari; R J Huxtable
Journal:  Eur J Pharmacol       Date:  1980-10-31       Impact factor: 4.432

8.  Evidence against the adenosine-catecholamine antagonism under in vivo conditions.

Authors:  R Seitelberger; W Schütz; O Schlappack; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

9.  The effects of amrinone on contractility, Ca2+ uptake and cAMP in smooth muscle.

Authors:  K D Meisheri; R F Palmer; C Van Breemen
Journal:  Eur J Pharmacol       Date:  1980-01-25       Impact factor: 4.432

10.  Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.

Authors:  T H LeJemtel; E Keung; E H Sonnenblick; H S Ribner; M Matsumoto; R Davis; W Schwartz; A A Alousi; D Davolos
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

View more
  5 in total

1.  Involvement of purine compounds in the inotropic action of milrinone.

Authors:  P Dorigo; R M Gaion; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

2.  Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

Authors:  M Ungerer; M Böhm; R H Schwinger; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

3.  Comparison between the cardiac effects induced by muzolimine and furosemide in guinea-pig atria.

Authors:  P Dorigo; R M Gaion; M Bergamin; A Giacometti; E Valentini; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

4.  New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.

Authors:  M Floreani; P Fossa; S Gessi; L Mosti; P A Borea; P Dorigo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

5.  An analysis of the mechanism of the inotropic action of some milrinone analogues in guinea-pig isolated atria.

Authors:  P Dorigo; R M Gaion; P Belluco; L Mosti; P A Borea; I Maragno
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.